Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunodeficiency and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAGT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAGT1 Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MAGT1 Products |
| Gene Delivery | MAGT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MAGT1 Products |
| Benchmark Ab | Anti-MAGT1 Recombinant Antibody Recombinant positive control. |
View MAGT1 Products |
| Validator | MAGT1 siRNA Set For knockdown verification. |
View MAGT1 Products |
| Related Target A | STT3B Catalytic subunit of the OST complex, functionally coupled with MAGT1 in N-glycosylation. |
View STT3B Products |
| Related Target B | STIM1 Involved in calcium store-operated calcium entry, regulated by MAGT1-mediated magnesium homeostasis. |
View STIM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | Lentivirus-mediated stable cell line expression to preserve native multi-pass conformation |
| Functional Readout (Mg2+/Ca2+ flux) | High-titer lentiviral transduction for robust assay development and stable signaling |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| Off-target Glycosylation Effects | Validated siRNA included for specificity checks |
Live MAGT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAGT1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to gene therapy and small molecule modulators of glycosylation. As first-generation therapies reach the clinic, the next wave of R&D is targeting MAGT1-mediated magnesium transport to rescue T-cell function and control viral infections in immunodeficient states.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy | Academic/NIH Consortia | XMEN Disease | Stable expression validation (Need high-titer Lentivirus) |
| Small Molecule | Oncology Biotechs | Solid Tumors (OST Modulation) | Selectivity assays vs STT3B (Need Target & Homolog panels) |
| Monoclonal Antibody | Immunology Research Labs | Viral Infections (EBV control) | Epitope mapping on native loops (Need Sequence Verified Proteins) |